Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

75.54 -0.21 (-0.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Exploring the Growth Potential of NASDAQ:CORT as It Nears a Breakout. ↗
Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout. 
Via Chartmill
News headline image
The Analyst Verdict: Corcept Therapeutics In The Eyes Of 4 Experts ↗
 
Via Benzinga
News headline image
CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗
CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Recap: Corcept Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 15, 2024 ↗
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
News headline image
Earnings Preview: Corcept Therapeutics ↗
 
Via Benzinga
News headline image
Despite its growth, NASDAQ:CORT remains within the realm of affordability. ↗
Looking for growth without the hefty price tag? Consider NASDAQ:CORT. 
Via Chartmill
News headline image
Corcept Completes Enrollment in Phase 4 CATALYST Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Mid-Cap Corcept Therapeutics Reveals Data From Hormonal Disorder Study, FDA Application Submission Expected This Quarter ↗
Insights from Corcept Therapeutics' Phase 3 GRACE trial results for endogenous Cushing's syndrome. Discover rapid improvements in hypertension and hyperglycemia without adverse effects. Join us for the... 
Via Benzinga
News headline image
Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
News headline image
Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗
In the world of growth stocks, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) shines as a value proposition. 
Via Chartmill
News headline image
Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation. ↗
For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering. 
Via Chartmill
News headline image
What's Going On With Stress Hormone Modulator-Focused Corcept Therapeutics' Stock Friday? ↗
Findings of Corcept Therapeutics' CATALYST study on Cushing's syndrome & difficult-to-control type 2 diabetes. 
Via Benzinga
News headline image
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. 
Via Chartmill
News headline image
Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Corcept Appoints Roberto Vieira as President, Oncology
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗
CORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock which is not overvalued. 
Via Chartmill
News headline image
Archer-Daniels-Midland, B. Riley Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Archer-Daniels-Midland Company (NYSE: ADM) fell sharply in today’s pre-market trading... 
Via Benzinga
News headline image
Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program
From Corcept Therapeutics Incorporated
Via GlobeNewswire
News headline image
Crude Oil Down 2%; Tesla Deliveries Top Estimates ↗
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to... 
Via Benzinga
Topics Stocks
News headline image
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS